While guidelines around clinical management of cancer risk in patients with GPV in BRCA1 and BRCA25 6 and the mismatch repair genes; MLH1, MSH2, MSH67 have been published, there are few guidelines on how to manage patients with GPV in genes associated with more moderate risks of OC: BRIP1, PALB2, RAD51D and RAD51C. This evidence concerns the gene RAD51C and cancer.